Paradigm Biopharmaceuticals (ASX:PAR) - Aktienkurs, Nachrichten und Analyse

PAR Aktienübersicht

Paradigm Biopharmaceuticals Limited beschäftigt sich mit der Erforschung und Entwicklung von therapeutischen Produkten für den menschlichen Gebrauch in Australien.

Über das Unternehmen

PAR grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	4/6
Dividenden	0/6

Belohnungen

Risikoanalyse

Hat weniger als 1 Jahr Cash Runway

Erzielt weniger als 1 Million USD an Einnahmen (A$42K)

Die Aktionäre wurden im vergangenen Jahr verwässert

Hat keine nennenswerte Marktkapitalisierung (A$103M)

+ 1 mehr Risiko

Paradigm Biopharmaceuticals Limited Wettbewerber

Cynata Therapeutics

ASX:CYP

AU$38.8m

Beroni Group

NSX:BTG

AU$75.9m

Noxopharm

ASX:NOX

AU$30.7m

Dimerix

ASX:DXB

AU$208.9m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Paradigm Biopharmaceuticals
Historische Aktienkurse
Aktueller Aktienkurs	AU$0.20
52-Wochen-Hoch	AU$0.78
52-Wochen-Tief	AU$0.17
Beta	0.94
11 Monat Veränderung	-20.41%
3 Monate Veränderung	-30.36%
1 Jahr Veränderung	-67.23%
33 Jahre Veränderung	-90.53%
5 Jahre Veränderung	-93.61%
Veränderung seit IPO	-47.30%

Aktuelle Nachrichten und Updates

Recent updates

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Aug 22

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Apr 17

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Sep 21

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Jun 20

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Dec 02

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Jun 07

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Feb 22

We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

Jan 24

Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

Dec 28

When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Nov 29

Aktionärsrenditen

	PAR	AU Biotechs	AU Markt
7D	-2.5%	-2.5%	0.3%
1Y	-67.2%	16.3%	16.1%

Rendite im Vergleich zur Industrie: PAR unter dem Niveau der Branche Australian Biotechs , die im vergangenen Jahr eine Rendite von 17.2% erzielte.

Rendite vs. Markt: PAR hinter dem Markt Australian zurück, der im vergangenen Jahr eine Rendite von 11.2 erzielte.

Preisvolatilität

Is PAR's price volatile compared to industry and market?
PAR volatility
PAR Average Weekly Movement	10.7%
Biotechs Industry Average Movement	10.5%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.2%
10% least volatile stocks in AU Market	3.6%

Stabiler Aktienkurs: PARDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: PARDie wöchentliche Volatilität (9%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2014	n/a	Paul Rennie	www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Limited beschäftigt sich mit der Erforschung und Entwicklung von therapeutischen Produkten für den menschlichen Gebrauch in Australien. Der führende Kandidat ist Zilosul, ein injizierbares Pentosanpolysulfat-Natrium-Medikament zur Behandlung von Osteoarthritis, Mukopolysaccharidose, Ross River Virus, Chikungunya Virus, chronischer Herzinsuffizienz, allergischen Atemwegserkrankungen und akutem Atemnotsyndrom. Das Unternehmen wurde im Jahr 2014 gegründet und hat seinen Hauptsitz in Melbourne, Australien.

Paradigm Biopharmaceuticals Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Paradigm Biopharmaceuticals im Vergleich zum Marktanteil des Unternehmens?
PAR grundlegende Statistiken
Marktanteil	AU$68.32m
Gewinn(TTM)	-AU$58.65m
Umsatz(TTM)	n/a

0.0x

Kurs-Umsatz-Verhältnis

-1.2x

Kurs-Gewinn-Verhältnis

Ist PAR zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
PAR Gewinn- und Verlustrechnung (TTM)
Einnahmen	AU$0
Kosten der Einnahmen	AU$8.99k
Bruttogewinn	-AU$8.99k
Sonstige Ausgaben	AU$58.64m
Umsatz	-AU$58.65m

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.17
Bruttomarge	0.00%
Nettogewinnspanne	0.00%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich PAR auf lange Sicht entwickelt?

Historische Performance und Vergleiche

PAR Aktienübersicht

Belohnungen

Risikoanalyse

Paradigm Biopharmaceuticals Limited Wettbewerber

ASX:CYP

AU$38.8m

NSX:BTG

AU$75.9m

ASX:NOX

AU$30.7m

ASX:DXB

AU$208.9m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 19, 2024

New minor risk - Profitability

Insufficient new directors

New minor risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Market cap size

Recent updates

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 19, 2024

New minor risk - Profitability

Insufficient new directors

New minor risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Market cap size

New minor risk - Share price stability

Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately

Consensus EPS estimates fall from profit to AU$0.18 loss

Forecast breakeven date pushed back to 2025

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Founder recently bought AU$76k worth of stock

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Paradigm Biopharmaceuticals Ltd Advises the First Safety Review Meeting of the Data Monitoring Committee (DMC) for the Pivotal Para_OA_002 Clinical Trial

Founder recently bought AU$62k worth of stock

Paradigm Biopharmaceuticals Limited Announces Executive Changes

Price target increased to AU$2.20

Paradigm Biopharmaceuticals Limited Announces an Abstract on Paradigm's Phase 2 Clinical Trial Evaluating Injectable Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Announces First UK Subject Randomised and Dosed for the Pivotal Phase 3 Trial for the Treatment of Pain Associated with Knee OA

Paradigm Biopharmaceuticals Ltd Announces Successful Primary Endpoint in Phase 2 Trial

Paradigm Biopharmaceuticals Ltd Provides an Update on the Ongoing Multi-Centre Double-Blind Randomised Phase 2 Study Comparing PPS to Placebo in Mucopolysaccharidosis Type VI (MPS-VI) Patients

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 18, 2022

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Limited Appoints Abby Macnish as Interim Company Secretary

Paradigm Biopharmaceuticals Ltd Announces MPS Clinical Program Update and Paradigm to Present At the International Conference on Lysosomal Diseases

Paradigm Biopharmaceuticals Limited Reports Important Global Progress for the Para_Oa_002 Phase 3 Clinical Trial Evaluating Zilosul® for Osteoarthritis

Paradigm Biopharmaceuticals Limited Announces PARA_OA_008 Study Evaluating Zilosul® Mechanism and Disease Modifying Effects Completes Recruitment

Forecast to breakeven in 2024

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Paradigm Biopharmaceuticals Limited Announces Chief Executive Officer Changes

Paradigm Biopharmaceuticals Limited Doses First US Subjects Under Phase 3 Trial

Price target decreased to AU$2.64

U.S. Food and Drug Administration Grants Fast Track Designation for Paradigm Biopharmaceuticals Ltd of Phase 3 Program

Founder & Non-Executive Chairman recently bought AU$51k worth of stock

Price target increased to AU$4.49

Consensus forecasts updated

No longer forecast to breakeven

Paradigm Biopharmaceuticals Limited Announces First Subjects Randomised and Dosed in Para_0A_002 Phase 3 Study in Australia

Paradigm Biopharmaceuticals Ltd Reports Postive Topline Results in Heart Failure Model

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Limited Reports Preliminary Results from Phase 2 Mps I Study

Paradigm Biopharmaceuticals Limited Announces First MPS-VI Patient Dosed Under Phase 2 Trial in Brazil Investigating PPS for the Treatment of MPS-VI

Paradigm Biopharmaceuticals Limited Receives Feedback from US FDA on IND Submission

Paradigm Biopharmaceuticals Limited Announces Australian Ethics Approval for Paradigm's ARA_OA_002 Pivotal Phase 3 Clinical Trial in Participants with Knee OA

Paradigm Biopharmaceuticals Limited Makes Progress with Investigational New Drug Application

Consensus EPS estimates increase to -AU$0.15

Paradigm Biopharmaceuticals Limited Receives Key Regulatory Approvals for MPS VI Study

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Ltd Receives First Revenue Through Physician Prescription of Zilosul to Patients Via the TGA SAS

Paradigm Biopharmaceuticals Ltd Provides an Update on its IND Application to the Us Food and Drug Administration

Paradigm Biopharmaceuticals Limited Updates Phase 2A, Randomised, Double-Blind, Placebo- Controlled Study

Analysts lower EPS estimates to -AU$0.17

New 90-day low: AU$2.28

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Paradigm Biopharmaceuticals Ltd Announces It Has Received Ethics Approval for Its Phase 2 Clinical Trial to Evaluate the Treatment Effects of Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Appoints Helen Fisher as Non-Executive Director and Chair of the Audit and Risk Committee

Paradigm Biopharmaceuticals Ltd Reports Ongoing Data Update on Patients Who Received Zilosul Under the Therapeutic Goods Administration (TGA) Special Access Scheme

Erträge & Einnahmen